Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA 2 min read People and Community Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA AETOSWire February 7, 2022 London, United Kingdom– (AETOSWire) Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with...Read More
